<DOC>
	<DOCNO>NCT00290147</DOCNO>
	<brief_summary>The purpose study exame safety DNA vaccine dengue-1 .</brief_summary>
	<brief_title>Safety Study Dengue Virus DNA Vaccine</brief_title>
	<detailed_description>Dengue desease affect 100 million people throughout world mainly tropical country South Pacific , Asia , Caribbean , Africa . The disease often present high fever , severe headache , joint/muscle pain usually go away , also present sometimes deadly hemorrhagic ( bleed ) disease . Humans catch disease bitten mosquito infect dengue virus . Scientists Naval Medical Research Center work vaccine prevent dengue disease . This vaccine , refer D1ME , experimental DNA vaccine contain gene dengue-1 virus . The purpose study test safety new experimental vaccine dengue see vaccine stimulate immune system .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Available participate duration study ( approximately 12 month ) Completion review knowledge assement quiz Pregnant ( history ascertain pregnancy test ) lactate female Female intend become pregnant study Plan elective surgery study period HIV infection Known immunodeficiency currently receive immunosuppressive therapy ( inhaled topical steroid allow ) History splenectomy Administration vaccine foreseen study protocol period start 30 day dose vaccine end 30 day vaccination Evidence active ( acute chronic ) hepatitis B C infection Autoimmune diseaseor subject describe firstdegree relative clearly document autoimmune disease Acute chronic , clinically significant cardiac , pulmonary , hepatic , renal abnormality , determine physical examination basic laboratory screen Clinical laboratory evidence significant anemia History flavivirus infection previous receipt flavivirus vaccine Positive serology flavivirus ( four dengue virus serotypes , Japanese encephalitis , Yellow fever virus , West Nile virus ) , HIV1 , Hepatitis B surface antigen , antihepatitis C virus antibody prior enrollment Use investigational nonregistered drug vaccine study vaccine within 60 day precede first dose study vaccine , plan use study period . Previous history allergic anaphylactic reaction vaccine Planned travel area endemic dengue study period Any significant finding , opinion investigator , would increase risk adverse outcome participate protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Dengue</keyword>
	<keyword>DNA vaccine</keyword>
</DOC>